Daniel P. Regan
Board Member
immunology
Duracare Home Medical Equipment
Dominica
Biography
Daniel P. Regan has broad pharmaceutical leadership experience across the spectrum of global commercialization, sales, and marketing of novel therapies for the treatment of chronic kidney disease. From 1999 to 2011, Mr. Regan held positions of increasing responsibility at Genzyme/Sanofi, leading multi-functional teams in sales, marketing, and commercialization of renal products. Mr. Regan’s career at Genzyme included his appointment as Global General Manager, Senior Vice President of the Renal franchise, with direct responsibility for all aspects of worldwide renal commercial operations, including the Renagel®/Renvela® phosphate binder franchise and the worldwide launch of Renvela®, growing the renal franchise to global revenue approaching $1 billion. From 2011 to 2012, Mr. Regan served as Chief Commercial Officer of Inspiration Biopharmaceuticals, which sold its main asset to Baxter International. Most recently, from 2012 until 2015, Mr. Regan was Chief Commercial Officer of Intercept Pharmaceuticals. Mr. Regan has a B.A. in Economics from the University of Massachusetts.
Research Interest
Daniel P. Regan has broad pharmaceutical leadership experience across the spectrum of global commercialization, sales, and marketing of novel therapies for the treatment of chronic kidney disease. From 1999 to 2011, Mr. Regan held positions of increasing responsibility at Genzyme/Sanofi, leading multi-functional teams in sales, marketing, and commercialization of renal products. Mr. Regan’s career at Genzyme included his appointment as Global General Manager, Senior Vice President of the Renal franchise, with direct responsibility for all aspects of worldwide renal commercial operations, including the Renagel®/Renvela® phosphate binder franchise and the worldwide launch of Renvela®, growing the renal franchise to global revenue approaching $1 billion. From 2011 to 2012, Mr. Regan served as Chief Commercial Officer of Inspiration Biopharmaceuticals, which sold its main asset to Baxter International. Most recently, from 2012 until 2015, Mr. Regan was Chief Commercial Officer of Intercept Pharmaceuticals. Mr. Regan has a B.A. in Economics from the University of Massachusetts.
